drugset
drugset / Trial / NCT03654716

Phase 1 Study of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric Cancer

NCT03654716 ↗

Phase 1 Completed 21 enrolled Dana-Farber Cancer Institute Aileron Therapeutics, Inc. · collabCookies for Kids' Cancer · collabTeamConnor Childhood Cancer Foundation · collab
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This research study is studying a novel drug called ALRN-6924 as a possible treatment for resistant (refractory) solid tumor, brain tumor, lymphoma or leukemia. The drugs involved in this study are: * ALRN-6924 * Cytarabine (for patients with leukemia only)

Timeline

Start
2018-11-01
Primary completion
2023-07-17
Completion
2023-07-17

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject SULANEMADLIN Peptide — Intravenous
Background Cytarabine Small molecule — Intravenous

Indications

brain neoplasm leukemia lymphoma